Viking Therapeutics Stock Climbs On Q2 EPS Beat
Viking Therapeutics Stock Climbs On Q2 EPS Beat
Research and development expenses were $23.8 million for the quarter, compared to $13.9 million for the same period in 2023. Viking said the increase was primarily due to increased expenses related to manufacturing for the company's drug candidates, clinical studies, pre-clinical studies, salaries and benefits and stock-based compensation.Viking Therapeutics, Inc. (NASDAQ:VKTX) shares are trading higher after the company reported its second-quarter financial results Wednesday. Here's a look at the key figures from the report.
Viking Therapeutics, Inc.（纳斯达克股票代码：VKTX）周三公布第二季度财务业绩后，该公司股价走高。以下是报告中的关键数据。
The Details: Viking Therapeutics reported quarterly losses of 20 cents per share which beat the analyst consensus estimate of losses of 27 cents by 25.93%.
详情：Viking Therapeutics公布的季度每股亏损为20美分，比分析师普遍预期的27美分亏损高出25.93％。
Viking reported a net loss of $22.3 million for the second quarter, compared to a net loss of $19.2 million in the corresponding period in 2023. The increase in net loss for the three months ended June 30, 2024, was primarily due to the increase in research and development expenses and general and administrative expenses, noted previously, partially offset by increased interest income, compared to the same period in 2023.
维京公布的第二季度净亏损为2,230万美元，而2023年同期的净亏损为1,920万美元。截至2024年6月30日的三个月，净亏损的增加主要是由于研发费用以及一般和管理费用的增加，与2023年同期相比，利息收入的增加部分抵消了上述增加。
Research and development expenses were $23.8 million for the quarter, compared to $13.9 million for the same period in 2023. Viking said the increase was primarily due to increased expenses related to manufacturing for the company's drug candidates, clinical studies, pre-clinical studies, salaries and benefits and stock-based compensation.
本季度的研发支出为2380万美元，而2023年同期为1,390万美元。维京表示，增长主要是由于与公司候选药物的制造、临床研究、临床前研究、工资和福利以及股票薪酬相关的费用增加。
Read Also: What's Going On With Meta Stock?
另请阅读：Meta Stock 怎么了？
"The first half of 2024 was marked by strong momentum in the company's pipeline programs, as we reported successful outcomes from three different clinical trials, and began preparing for next steps with each program," stated Brian Lian, Ph.D., CEO of Viking.
Viking首席执行官Brian Lian博士表示：“2024年上半年公司的研发项目势头强劲，我们报告了三项不同的临床试验的成功结果，并开始为每个项目的下一步做准备。”
"The Phase 2 VENTURE study of VK2735 in obesity demonstrated up to an approximately 15% reduction in body weight from baseline following 13 weeks of dosing, as well as promising safety and tolerability. Following receipt of written feedback from an FDA Type C meeting, we are advancing this compound into Phase 3 development. We are currently preparing for an end of Phase 2 meeting with the agency, which we expect to occur later this year," Lian added.
“VENTURE 对 VK2735 治疗肥胖症的第二阶段研究表明，在给药 13 周后，体重比基线减少了大约 15%，并且安全性和耐受性令人鼓舞。在收到美国食品和药物管理局C类会议的书面反馈后，我们正在将该化合物推进到第三阶段的开发。我们目前正在为结束与该机构的第二阶段会议做准备，预计该会议将于今年晚些时候举行。” Lian补充说。
VKTX Price Action: According to Benzinga Pro, Viking Therapeutics shares are up 10.10% after-hours at $55.50 at the time of publication Wednesday.
VKTX价格走势：根据Benzinga Pro的数据，截至周三发布时，Viking Therapeutics股价盘后上涨10.10％，至55.50美元。
- What's Going On With Riot Platforms Stock?
- Riot Platforms 的股票怎么了？
Image: Csaba Nagy from Pixabay
图片：来自 Pixabay 的 Csaba Nagy